Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The ESMO Immuno-Oncology Congress 2025 is a global congress dedicated to the rapidly advancing field of cancer immunotherapy, uniting clinicians, researchers, and industry innovators to explore breakthroughs shaping patient care. VJOncology has brought you comprehensive coverage, including expert interviews, key trial updates, and in-depth discussions on the evolving landscape of immuno-oncology. See our latest insights, videos, and highlights from ESMO Immuno-Oncology 2025 below.
View all videos

ESMO Immuno-Oncology 2025

10–12 December 2025 | London, UK

ESMO Immuno-Oncology 2025

10–12 December 2025 | London, UK
The ESMO Immuno-Oncology Congress 2025 is a global congress dedicated to the rapidly advancing field of cancer immunotherapy, uniting clinicians, researchers, and industry innovators to explore breakthroughs shaping patient care. VJOncology has brought you comprehensive coverage, including expert interviews, key trial updates, and in-depth discussions on the evolving landscape of immuno-oncology. See our latest insights, videos, and highlights from ESMO Immuno-Oncology 2025 below.
View all videos

Watch our latest ESMO Immuno-oncology videos!

View all
2:40
CRISPR screening reveals MED16 as a novel immunotherapy target
Dimitrios Garyfallos • 25 Nov 2025
4:55
Management of liver metastases in solid microsatellite stable cancers
Niels Halama • 26 Nov 2025
1:54
Spatial T-cell communities and their impact on immunotherapy response
Abhishek Garg • 5 Dec 2025
1:13
Highlighting the role of HPV vaccines in precenting HPV-associated cancers
Amanda Psyrri • 12 Dec 2025

Cancer vaccine updates

View all
1:09
Off-the-shelf cancer vaccines targeting tumor microenvironment antigens
Mads Andersen • 5 Dec 2025
1:15
The future of intratumoral immunotherapies in solid tumors
Angelica Loskog • 27 Nov 2025

Checkpoint inhibitor updates

View all
1:14
How can immunotherapy refractory melanoma be treated in the clinic?
Inge Marie Svane • 15 Dec 2025
2:14
Neoadjuvant ICI reshapes B cell immunity in MMRd endometrial cancer
Hans Nijman • 4 Dec 2025

Antibody-drug conjugate updates

View all
4:22
How are ADC and ICI combinations redefining breast cancer treatment?
Laurence Buisseret • 15 Dec 2025
1:08
Monitoring ADC and checkpoint inhibitor-related toxicity in oncology
Laurence Buisseret • 15 Dec 2025

Bispecific antibody updates

View all
3:03
Emerging CAR-T and bispecific antibody strategies in solid tumors
Sebastian Kobold • 11 Dec 2025
2:50
First-in-human study of INCA32459, a LAG-3/PD-1 bsAb in advanced cancers
Jesus Fuentes-Antras • 18 Dec 2025
The content of VJOncology is intended for healthcare professionals